# US 2008/0187914 A1 · Induced Heteroduplex Generators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187914 A1
- Document ID: US20080187914A1
- Status: Published application
- Kind: A1
- Application number: 11/664,908
- Filed: 2005-10-10
- Published: 2008-08-07
- Earliest claimed: 2004-10-08
- Assignees: IHG Pharmaco Ltd.
- Inventors: Louise Anne Tilley
- Web page: https://patentgrep.com/patent/US20080187914A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Heteroduplex band resolution is found to be improved by modifying the induced heteroduplex generator (IHG) molecule such that the identifier is spaced apart from the nucleotide position immediately adjacent to the site of the polymorphism which is to be genotyped. Unexpectedly, it is found that, when such modified IHG molecules are used, the resolution of the induced heteroduplexes is significantly improved.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A method for genotyping a target gene sequence associated with an inherited genetic disorder, comprising:
(a) providing a population of induced heteroduplex generator (IHG) molecules corresponding to said target gene sequence, the IHG molecule being a synthetic DNA sequence including at least one nucleotide position which corresponds to a known polymorphic site in the genomic DNA sequence of the target gene sequence and at least one nucleotide substitution, deletion and/or insertion (“identifier”) relative to the genomic sequence at a nucleotide position spaced by a distance of at least one base from the nucleotide position which corresponds to the known polymorphic site and wherein the nucleotide(s) between the nucleotide position which corresponds to the polymorphic site and the identifier are unchanged from the genomic sequence; wherein the at least one identifier comprises an insertion of one or more bases and the IHG molecule is selected to provide improved separation of the resolved bands by a method comprising comparing the separation obtained using the IHG molecule with the separation obtained using a corresponding IHG in which the identifier is not so spaced;
(b) providing a population of the target gene sequence;
(c) combining the respective populations of (a) and (b) under conditions suitable for heteroduplex formation, to obtain induced heteroduplexes between the target gene sequence and an IHG molecule corresponding to said target gene sequence;
(d) resolving the induced heteroduplexes into bands on a suitable support; and
(e) analysing the resolved induced heteroduplexes to determine the genotype of the target gene sequence.

### Claim 37 (depends on 36)

A method according to claim 36, wherein the polymorphic site in the genomic DNA sequence is a single nucleotide polymorphism (SNP).

### Claim 38 (depends on 36)

A method according to claim 36, wherein the at least one identifier included in the synthetic DNA relative to the genomic sequence comprises an insertion of one base.

### Claim 39 (depends on 36)

A method according to claim 36, wherein the at least one identifier included in the synthetic DNA relative to the genomic sequence comprises an insertion of more than one base.

### Claim 40 (depends on 36)

A method according to claim 36, wherein the at least one identifier included in the synthetic DNA relative to the genomic sequence consists of an insertion of one base.

### Claim 41 (depends on 36)

A method according to claim 36, wherein the at least one identifier included in the synthetic DNA relative to the genomic sequence consists of an an insertion of more than one base.

### Claim 42 (depends on 36)

A method according to claim 36, wherein the genomic sequence includes a plurality of known polymorphic sites and the identifier is spaced by a distance of at least one base from the nucleotide position(s) which correspond to each of the known polymorphic sites.

### Claim 43 (depends on 36)

A method according to claim 36, wherein the insertion is a series of identical bases.

### Claim 44 (depends on 43)

A method according to claim 43, wherein the identical bases are A nucleotides.

### Claim 45 (depends on 43)

A method according to claim 43, wherein the identical bases area G nucleotides.

### Claim 46 (depends on 43)

A method according to claim 43, wherein the synthetic DNA sequence is single stranded.

### Claim 47 (depends on 36)

A method according to claim 36, wherein the synthetic DNA sequence is double stranded.

### Claim 48 (depends on 36)

A method according to claim 36, wherein the synthetic DNA sequence is substantially identical in length to a gene segment of the genomic DNA under consideration, disregarding any inserted or deleted bases of the IHG.

### Claim 49 (depends on 36)

A method according to any one of claim 36, wherein the synthetic DNA sequence is a different length than a gene segment of the genomic DNA under consideration, disregarding any inserted or deleted bases of the IHG.

### Claim 50 (depends on 36)

A method according to claim 36, wherein the resolving of the induced heteroduplexes is performed using electrophoresis.

### Claim 51

A method for predicting the likelihood that an organism, for example a human or other mammalian subject, will be susceptible to a particular genetic condition or disorder associated with a particular genotype, the method comprising genotyping in accordance with any one of the preceding claims a target gene sequence of the organism believed to be relevant to the genetic condition or disorder, and analyzing the results of the genotyping to predict the presence, absence, likelihood of the presence or absence, or severity of the particular condition or disorder in the organism.

### Claim 52 (depends on 51)

A method according to claim 51, wherein the genotyping is performed with respect to a particular single nucleotide polymorphism (SNP) at a specific location of a gene.

### Claim 53 (depends on 36)

A method according to claim 36, wherein the inherited genetic disorder is selected from cystic fibrosis, phenylketonuria, sickle cell disease and β-thalassaemia, the −1082 polymorphism in the promoter of the IL-10 gene, and the −238 polymorphism in the tumour necrosis factor (TNF) gene promoter.

### Claim 54

Use, in genotyping the “−1082” polymorphism in the promoter of the IL-10 gene, of an IHG having the following sequence:
AATCCAAGACAACACTACTAAGGCTTGTTTGGGAGAGAAAAGGGAAGTAG
GGATAGGTAAGAGGAAAGTAAGGGACCTCCTATCCAG

### Claim 55

Use, in genotyping the “−1082” polymorphism in the promoter of the IL-10 gene, of an IHG having the following sequence:
AATCCAAGACAACACTACTAAGGCTTGTTTGGGAGAGAAAAGGGAAGTAG
GGATAGGTAAGAGGAAAGTAAGGGACCTCCTATCCAG

### Claim 56

Use, in genotyping the “−1082” polymorphism in the promoter of the IL-10 gene, of an IHG having the following sequence:
AATCCAAGACAACACTACTAAGGCTTGTTTGGGAGAGGGAAAAGAAGTAG
GGATAGGTAAGAGGAAAGTAAGGGACCTCCTATCCAG

### Claim 57

Use, in genotyping the “−238” polymorphism in the Tumour Necrosis Factor gene, of an IHG having the following sequence:
GTTCAGCCTCCAGGGTCCTACACACAAATCAGTGGCCCAGAAGACCCCCC
TCAGAATCGGAAAAAGCAGGGAGGATGGGGAGTGTGAGGGGTATCCTTGA
TGCTTGTGTGTCCCCAACTTTCCAAATCCC

### Claim 58

Use, in genotyping the “−238” polymorphism in the Tumour Necrosis Factor gene, of an IHG having the following sequence:
GTTCAGCCTCCAGGGTCCTACACACAAATCAGTCAGTGGCCCAGAAGACC
CCCCTCAGAATCGGAGAAAACAGGGAGGATGGGGAGTGTGAGGGGTATCC
TTGATGCTTGTGTGTCCCCAACTTTCCAAATCCC
